Mainz (ots) - In der ersten Ausgabe 2018 blickt "ZDFzoom" auf Themen vergangener investigativer Dokumentationen ...
Resverlogix's Lead Drug Featured in Key Scientific Publication
Calgary, Canada (ots/PRNewswire) - - RVX-208 is the Only Apo-Al/HDL Drug to be Highlighted
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that Resverlogix's lead drug is featured prominently in an article titled "Emerging Antidyslipidemic Drugs", which appears in the current edition of Expert Opinion of Emerging Drugs, a well respected scientific journal for the pharmaceutical industry. The article written by Drs.' Pollex, Joy and Hegele provides an overview of current and upcoming dyslipidemic drugs.
"To be the only ApoA-l/HDL drug highlighted in an esteemed journal such as Expert Opinion of Emerging Drugs speaks volumes as to the excitement felt in the scientific community for our lead drug RVX-208," stated Donald McCaffrey, President and CEO of Resverlogix. "The data provided to the authors was our preclinical data. The Phase 1a data which we recently announced illustrated very similar trending as the African Green Monkey data of increased ApoA-I production and HDL functionality, thus our enthusiasm continues to build as we head into our Phase 1b/2a trial later this year."
RVX-208 is a first-in-class small molecule that facilitates endogenous ApoA-I production. It is positioned as one of the most promising emerging drugs in the treatment of atherosclerosis, the largest medical market in the world with a critical unmet need. To the Company's knowledge RVX-208 is the only novel small molecule that is specifically designed to increase ApoA-I production. Consequently this raises functional HDL levels which in turn enhance reverse cholesterol transport, atherosclerosis regression and ultimately reduction of major adverse cardiovascular events (MACE).
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's disease and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit http://www.resverlogix.com.
This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.
For further information: Theresa Kennedy, VP, Corporate Communications, Resverlogix Corp., Phone: +1-604-538-7072, Email: Theresa@resverlogix.com; Ken Lebioda, SVP Business & Corporate Dev't, Resverlogix Corp., Phone: +1-403-254-9252, Email: Ken@resverlogix.com; Website: http://www.resverlogix.com
For further information: Theresa Kennedy, VP, Corporate
Communications, Resverlogix Corp., Phone: +1-604-538-7072, Email:
Theresa@resverlogix.com; Ken Lebioda, SVP Business & Corporate Dev't,
Resverlogix Corp., Phone: +1-403-254-9252, Email:
Ken@resverlogix.com; Website: http://www.resverlogix.com